$55M for Boston-Power, Sequenom Plows Ahead with Exact Sciences Takeover Attempt, Nuance Announces $175M Stock Sale, & More Boston-Area Deals News
Summary
$55M for Boston-Power, Sequenom Plows Ahead with Exact Sciences Takeover Attempt, Nuance Announces $175M Stock Sale, & More Boston-Area Deals News Everything else around here is frozen solid this week (hello, minus two degrees real-feel! —Two Massachusetts firms—Alnylam Pharmaceuticals (NASDAQ: ALNY) of Cambridge and Cubist Pharmaceuticals (NASDAQ: CBST) of Lexington—inked a marketing deal focused on Alnylam’s RNAi-based treatment for respiratory syncytial virus, or RSV. —Cancer drug developer Kolltan Pharmaceuticals of New Haven, CT—a spinoff of Yale University Medical School—closed a Series A round worth an impressive $35 million. —Another cancer drug company, Cambridge, MA-based Forma Therapeutics, inked a license and option agreement with Novartis potentially worth more than $200 million. Direct, which handles online orders for clothing chains Gap, Banana Republic, Old Navy, and Piperlime—for its system of robotic warehouse workers.
Funding
Review available funding amount, funding date, investors, and linked company information related to $55M for Boston-Power, Sequenom Plows Ahead with Exact Sciences Takeover Attempt, Nuance Announces $175M Stock Sale, & More Boston-Area Deals News in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
